Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe.
/PRNewswire/ Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer. Romero, a.
Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) and Celdara Medical today announced the signing of a Memorandum of Understanding (MOU) aimed at identifying and advancing promising new therapeutics in areas of high unmet medical need.
Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled "Transforming Drug Development for Neurological Disorders: Proceedings from a Multi-disease Area Workshop," now published in Neurotherapeutics, The Journal of the American Society for Experimental Neurotherapeutics.
/PRNewswire/ Today, the National Organization for Rare Disorders (NORD®) launched a new education series in English and Spanish titled, "Rare Disease Drug.